RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SkinBioTherapeutics Stock

SkinBioTherapeutics ROA 2024

SkinBioTherapeutics ROA

-1.09

Ticker

SBTX.L

ISIN

GB00BF33H870

WKN

A2DPW8

In 2024, SkinBioTherapeutics's return on assets (ROA) was -1.09, a 20.73% increase from the -0.91 ROA in the previous year.

SkinBioTherapeutics Aktienanalyse

What does SkinBioTherapeutics do?

SkinBioTherapeutics PLC is an innovative biotechnology company specialized in the development of skincare products. The company was founded in 2016 in Manchester, United Kingdom, and has since been led by a team of experienced scientists and entrepreneurs. The company's CEO, Dr. Catherine O'Neill, founded SkinBioTherapeutics PLC with the goal of developing innovative skincare products based on the latest scientific findings. The company focuses on the development of products using probiotic bacteria, which have been found to influence the immune system. SkinBioTherapeutics PLC is divided into three divisions: skincare, medical applications, and cosmetics. The skincare division develops products specifically tailored to the needs of individuals with sensitive and problematic skin, aiming to improve the skin's immune system and reduce inflammation and irritation. The medical applications division focuses on the use of probiotic bacteria in treating skin conditions such as psoriasis, eczema, and acne. The cosmetics division, under the brand "SkinBiotix," develops products to improve skin health and appearance. Currently, SkinBioTherapeutics PLC offers several products, including SkinBiotix Balance, a skincare cream for sensitive and problematic skin, SkinBiotix Cleanse, a gentle water-based cleanser, and SkinBiotix Strengthen, a rich moisturizer for dry and problematic skin. With its unique technology platform and strong emphasis on research and development, SkinBioTherapeutics PLC is well-positioned to continue growing and bringing its innovative products to market. SkinBioTherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding SkinBioTherapeutics's Return on Assets (ROA)

SkinBioTherapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing SkinBioTherapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider SkinBioTherapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in SkinBioTherapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about SkinBioTherapeutics stock

What is the Return on Assets (ROA) of SkinBioTherapeutics this year?

The Return on Assets (ROA) of SkinBioTherapeutics is -1.09 undefined this year.

What was the ROA of SkinBioTherapeutics compared to the previous year?

The ROA of SkinBioTherapeutics has increased by 20.73% compared to the previous year.

What consequences do high ROA have for investors of SkinBioTherapeutics?

A high ROA is advantageous for investors of SkinBioTherapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in SkinBioTherapeutics?

A low ROA can be unfavorable for investors of SkinBioTherapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of SkinBioTherapeutics affect the company?

An increase in ROA of SkinBioTherapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of SkinBioTherapeutics impact the company?

A reduction in the ROA of SkinBioTherapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of SkinBioTherapeutics?

Some factors that can influence the ROA of SkinBioTherapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of SkinBioTherapeutics important for investors?

The ROA of SkinBioTherapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can SkinBioTherapeutics take to improve ROA?

To improve ROA, SkinBioTherapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does SkinBioTherapeutics pay?

Over the past 12 months, SkinBioTherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SkinBioTherapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of SkinBioTherapeutics?

The current dividend yield of SkinBioTherapeutics is .

When does SkinBioTherapeutics pay dividends?

SkinBioTherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SkinBioTherapeutics?

SkinBioTherapeutics paid dividends every year for the past 0 years.

What is the dividend of SkinBioTherapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is SkinBioTherapeutics located?

SkinBioTherapeutics is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von SkinBioTherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SkinBioTherapeutics from 12/4/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 12/4/2024.

When did SkinBioTherapeutics pay the last dividend?

The last dividend was paid out on 12/4/2024.

What was the dividend of SkinBioTherapeutics in the year 2023?

In the year 2023, SkinBioTherapeutics distributed 0 GBP as dividends.

In which currency does SkinBioTherapeutics pay out the dividend?

The dividends of SkinBioTherapeutics are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SkinBioTherapeutics

Our stock analysis for SkinBioTherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SkinBioTherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.